Kamada Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Kamada Ltd. on August 10, 2015, for the month of August 2015. The filing serves to disclose specific terms regarding the company's Series C Debentures for the period commencing June 1, 2015, and ending August 31, 2015.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, total debt, or liquidity. The only financial metric disclosed is the interest rate for the Series C Debentures:
- Series C Debenture Interest Rate (June 1 - August 31, 2015): 1.54264%
- Annualized Interest Rate: 6.17056%
- Payment Date: September 1, 2015
- Record Date: August 20, 2015
- Ex-Date: August 20, 2015
Material Changes
The filing does not report material changes in financial performance or operations compared to prior periods. It solely announces the calculated interest rate for the current quarter's debenture payment.
Guidance, Outlook, and Risks
The document includes a cautionary note regarding forward-looking statements. Management highlights that actual results may differ materially from expectations due to several risks, including:
- Unexpected results of clinical trials.
- Delays or denial in U.S. FDA or EMA approval processes.
- Additional competition in the Alpha-1 Antitrypsin Deficiency (AATD) market.
- Further regulatory delays.
The company states it undertakes no obligation to update these forward-looking statements except as required by law.
Key Facts for Investor Verification
- Verify the record date of August 20, 2015, to determine eligibility for the September 1, 2015, interest payment.
- Confirm the annualized interest rate of 6.17056% for the Series C Debentures.
- Monitor upcoming clinical trial results and regulatory approvals from the FDA and EMA, as these are cited as primary risks to future performance.